CINECA IRIS Institutional Research Information System

GIORDANO, Silvia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.390
EU - Europa 4.921
AS - Asia 4.305
SA - Sud America 89
AF - Africa 73
OC - Oceania 62
Continente sconosciuto - Info sul continente non disponibili 12
Totale 17.852
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.219
CN - Cina 2.572
IT - Italia 1.106
IE - Irlanda 586
DE - Germania 554
SE - Svezia 511
SG - Singapore 499
FR - Francia 447
UA - Ucraina 371
GB - Regno Unito 350
KR - Corea 314
FI - Finlandia 312
JP - Giappone 221
PL - Polonia 180
IN - India 133
CA - Canada 120
VN - Vietnam 115
AT - Austria 82
TW - Taiwan 80
NL - Olanda 77
TR - Turchia 76
ID - Indonesia 74
HK - Hong Kong 72
ES - Italia 69
BE - Belgio 52
AU - Australia 50
BR - Brasile 49
IR - Iran 46
MX - Messico 42
RU - Federazione Russa 37
EG - Egitto 33
GR - Grecia 29
MY - Malesia 29
CZ - Repubblica Ceca 28
CH - Svizzera 25
TH - Thailandia 22
CL - Cile 17
PT - Portogallo 16
RO - Romania 16
HU - Ungheria 14
DK - Danimarca 13
NZ - Nuova Zelanda 12
SN - Senegal 12
AR - Argentina 11
EU - Europa 10
IL - Israele 10
NO - Norvegia 9
AM - Armenia 8
HR - Croazia 7
RS - Serbia 7
SK - Slovacchia (Repubblica Slovacca) 7
ZA - Sudafrica 7
GT - Guatemala 6
SI - Slovenia 6
UZ - Uzbekistan 6
KE - Kenya 5
NG - Nigeria 5
PE - Perù 5
CO - Colombia 4
LK - Sri Lanka 4
DZ - Algeria 3
GH - Ghana 3
MO - Macao, regione amministrativa speciale della Cina 3
QA - Qatar 3
SA - Arabia Saudita 3
BG - Bulgaria 2
ET - Etiopia 2
IM - Isola di Man 2
JO - Giordania 2
OM - Oman 2
PH - Filippine 2
PK - Pakistan 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AP - ???statistics.table.value.countryCode.AP??? 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
GE - Georgia 1
KZ - Kazakistan 1
LB - Libano 1
LT - Lituania 1
LV - Lettonia 1
MK - Macedonia 1
MM - Myanmar 1
MU - Mauritius 1
PS - Palestinian Territory 1
PY - Paraguay 1
SV - El Salvador 1
YE - Yemen 1
Totale 17.852
Salva come PNG Salva come JPEG
Città #
Chandler 933
Ann Arbor 810
Beijing 808
Dublin 584
Fairfield 534
Houston 453
Singapore 341
Woodbridge 300
Ashburn 288
Wilmington 266
Dearborn 250
Jacksonville 240
Villeurbanne 234
Princeton 209
Seattle 201
Shanghai 196
Cambridge 194
Medford 187
Guangzhou 179
Nyköping 175
Torino 165
Warsaw 142
Redwood City 137
Nanjing 130
Pisa 115
Boston 100
Hangzhou 97
Milan 96
Turin 87
Vienna 75
Jakarta 67
Jinan 67
Wuhan 62
Dong Ket 61
Zhengzhou 60
Boardman 53
Cagliari 52
Tokyo 51
New York 47
Taipei 46
Chengdu 45
Shenyang 44
Hefei 41
San Diego 41
Fremont 40
Los Angeles 40
Brussels 39
Santa Clara 39
Tianjin 37
Munich 36
Toronto 34
Changsha 33
Verona 33
Falls Church 29
London 29
Pittsburgh 29
Rome 28
Ottawa 27
Kunming 26
Changchun 25
Helsinki 25
Norwalk 25
Seoul 25
Xian 25
Groningen 24
Hebei 23
Buffalo 22
Chongqing 22
Eschweiler 22
Madrid 20
Nanchang 20
Florence 19
Mountain View 18
Philadelphia 18
Washington 18
Silver Spring 17
Barcelona 16
Genoa 16
Lachine 16
Phoenix 16
Mumbai 15
Hong Kong 14
Harbin 13
Istanbul 13
Amsterdam 12
Central District 12
Dallas 12
Düsseldorf 12
Fuzhou 12
Shenzhen 12
Bangkok 11
Bethesda 11
Brescia 11
Carrara 11
Tehran 11
Upper Marlboro 11
Budapest 10
Delhi 10
Lanzhou 10
Nanning 10
Totale 10.427
Salva come PNG Salva come JPEG
Nome #
The Dual Roles of NRF2 in Cancer 2.192
YAP activation is an early event and a potential therapeutic target in liver cancer development. 714
MicroRNA/gene profiling unveils early molecular changes and NRF2 activation in a rat model recapitulating human HCC. 415
How Can Gastric Cancer Molecular Profiling Guide Future Therapies? 392
MicroRNAs: New tools for diagnosis, prognosis and therapy in hepatocellular carcinoma? 326
Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. 306
Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. 292
Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts 284
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. 271
Enhanced c-Met activity promotes G-CSF induced mobilization of hematopoietic progenitor cells via ROS signaling. 250
Only a subset of Met-activated pathways are required to sustain oncogene addiction 245
By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy. 238
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study 236
Personalized therapeutic strategies in HER2-driven gastric cancer 233
A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits 213
YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC 207
BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody 204
Expression of c-jun is not mandatory for mouse hepatocyte proliferation induced by two nuclear receptor ligands: TCPOBOP and T3 199
Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective. 193
Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies 185
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies 185
Resistance to targeted therapies: a role for microRNAs? 182
Met as a therapeutic target in HCC: Facts and hopes. 181
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts 175
MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. 172
Istologia Medica 160
Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor 160
Cytokeratin-19 positivity is acquired along cancer progression and does not predict cell origin in rat hepatocarcinogenesis 154
Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis 146
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. 142
MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer. 141
Activation of RAS family members confers resistance to ROS1 targeting drugs. 136
miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling 136
c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. 134
A long term, non-tumorigenic rat hepatocyte cell line and its malignant counterpart, as tools to study hepatocarcinogenesis 134
Downregulating Neuropilin-2 Triggers a Novel Mechanism Enabling EGFR-Dependent Resistance to Oncogene-Targeted Therapies 133
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. 130
Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth 128
Biosynthesis of the protein encoded by the c-met proto-oncogene 122
Targeted therapies in cancer and mechanisms of resistance. 119
From single- to multi- target drugs in cancer therapy: when aspecificity becomes an advantage 117
Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort 117
A point mutation in the MET oncogene abrogates metastasis without affecting transformation. 112
Shedding-generated Met receptor fragments can be routed to either the proteasomal or the lysosomal degradation pathway. 108
Targeted therapies for gastric cancer: failures and hopes from clinical trials 107
MicroRNAs impair MET-mediated invasive growth 107
Different point mutations in the met oncogene elicit distinct biological properties. 106
MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer 101
Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. 94
The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. 92
Cytokine Induced Killer cells immunotherapy overcomes the resistance to MET tyrosine kinase inhibitors in nonsmall cell lung cancer 92
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib 90
Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. 88
Clinical implications of DNA repair defects in high-grade serous ovarian carcinomas 87
C-met activation is necessary but not sufficient for liver colonization by B16 murine melanoma cells. 85
ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. 84
Molecular cancer therapy: can our expectation be met? 84
The Semaphorin 4D receptor controls invasive growth by coupling with Met 84
Abstract 5603: Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies 84
Tyrosine kinase receptor indistinguishable from the c-met protein. 82
Specific uncoupling of GRB2 from the Met receptor. Differential effects on transformation and motility 82
Structural and functional domains critical for constitutive activation of the HGF-receptor (Met). 80
A natural hepatocyte growth factor/scatter factor autocrine loop in myoblast cells and the effect of the constitutive Met kinase activation on myogenic differentiation 80
A novel strategy for combination of clofarabine and pictilisib is synergistic in gastric cancer 80
Nrf2, but not β-catenin, mutation represents an early event in rat hepatocarcinogenesis. 79
Ets up-regulates MET transcription 79
Plexin signaling hampers integrin-based adhesion, leading to Rho-kinase independent cell rounding, and inhibiting lamellipodia extension and cell motility 79
Control of invasive growth by the HGF receptor family. 77
Defective posttranslational processing activates the tyrosine kinase encoded by the MET proto-oncogene (hepatocyte growth factor receptor). 76
C-terminal truncated forms of Met, the hepatocyte growth factor receptor. 76
CD100/Plexin-B1 interactions sustain proliferation and survival of normal and Leukemic CD5+ B lymphocytes 75
Altered regulation of receptor associated-tyrosine kinases in human tumors 75
Proteins phosphorylated on tyrosine as markers of human tumor cell lines 73
The landscape of d16HER2 splice variant expression across HER2-positive cancers 73
The c-met/HGF receptor in human tumours. 72
Evidence for autocrine activation of a tyrosine kinase in a human gastric carcinoma cell line. 72
The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival 70
Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity 68
Hepatocyte growth factor is a regulator of monocyte-macrophage function 68
Human ASH-1 Promotes Neuroendocrine Differentiation in Androgen Deprivation Conditions and Interferes With Androgen Responsiveness in Prostate Cancer Cells. 67
HGF/MET signaling protects Plasmodium infected host cells from apoptosis 66
Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas 66
Autocrine signaling of NRP1 ligand galectin-1 elicits resistance to BRAF-targeted therapy in melanoma cells 66
A non-dividing cell population with high pyruvate dehydrogenase kinase activity regulates metabolic heterogeneity and tumorigenesis in the intestine 66
Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis 65
HIF-1α stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. 65
Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages 64
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. 64
Semaphorin 4D regulates gonadotropin hormone-releasing Hormone-1 neuronal migration through Plexin B1-Met Complex 63
TGFalpha expression impairs Trastuzumab-induced HER2 downregulation 62
Drug development of met inhibitors: targeting oncogene addiction and expedience 62
Nrf2 Mutation/Activation Is Dispensable for the Development of Chemically Induced Mouse HCC 61
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers 61
Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. 60
Protein kinase-c activation inhibits tyrosine phosphorylation of the c-met protein. 60
Silencing the MET oncogene leads to regression of experimental tumors and metastases 60
Il cancro 59
Local hypothyroidism favours the progression of rat preneoplastic lesions to HCC. 59
MET overexpression turns human primary osteoblasts into osteosarcomas 59
Hepatocyte growth factor and its receptor are required for malaria infection 58
Totale 15.233
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.659
article - articoli 0
book - libri 0
conference - conferenze 649
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.308
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.229 0 0 0 250 208 445 338 197 273 216 201 101
2020/20212.130 152 130 168 236 150 144 215 105 208 204 145 273
2021/20222.896 198 227 225 290 133 119 166 158 121 199 586 474
2022/20233.123 325 234 94 263 315 686 223 204 376 64 194 145
2023/20241.832 242 288 102 121 97 224 88 107 52 126 167 218
2024/2025637 91 262 152 132 0 0 0 0 0 0 0 0
Totale 18.379